A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia.

Trial Profile

A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Atorvastatin (Primary) ; Atorvastatin/losartan (Primary) ; Losartan
  • Indications Essential hypertension; Hyperlipidaemia
  • Focus Therapeutic Use
  • Sponsors HanAll Biopharma
  • Most Recent Events

    • 22 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2013 to 1 Oct 2014.
    • 06 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top